ALCLS Cellectis SA

Cellectis to Participate in Upcoming Investor Conferences

Cellectis to Participate in Upcoming Investor Conferences

NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), will present at several upcoming investor conferences. Webcast information when available will be posted in the Investor Relations section of the Company’s website at 

Citi Annual BioPharma Conference September 9, 2020 from 3:20 PM to 4:05 PM EDT

André Choulika, Chairman & CEO, to participate in a panel on Innovation in Cell Therapy.

Wells Fargo Healthcare Conference Boston September 10, 2020 from 8:00 AM to 8:30 AM EDT

André Choulika; Carrie Brownstein, CMO; Simon Harnest, VP, Corporate Strategy & Finance to provide a company presentation.

Baird’s 2020 Global Healthcare Conference September 10, 2020 at 3:10 PM EDT

Simon Harnest to participate in a firechat and a live Q&A.

Bank of America Healthcare Conference London September 17, 2020 from 4:55 AM to 5:45 AM EDT

André Choulika to provide a company presentation.

About Cellectis

Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).

Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit .

Follow Cellectis on social media: , and .

TALEN® is a registered trademark owned by Cellectis.

For further information, please contact:

Media contacts:

Jennifer Moore, VP of Communications, 917-580-1088,

Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241,

IR contact:

Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008,

PDF available at: 

EN
02/09/2020

Underlying

ALCLSCellectis SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectis SA

 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Information mensuelle relative au nombre total des droits de vote et d...

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 07 oct. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 DateNombre total d’actionscomposant le capital socialNombre total de droits devote30/09/2025100 325 22989 413 272 Pour de plus amples informations sur Cellectis, veuillez contacter : Contacts média : Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, Chief of Staff...

7h / 28m 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets authority) PARIS, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of votingrights09/30/2025100,325,22989,413,272 For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations contact: Arthur S...

7h / 28m 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Edit...

Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that findings highlighting the strong potential of circular single-stranded DNA (CssDNA) as a universal, efficient non-viral template for gene therapy, along with a comprehensive study of TALE base editors (TALEB) off-targets in the nu...

21h / 18m 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis présentera des données sur son programme de thérapie génique...

Cellectis présentera des données sur son programme de thérapie génique non-virale et sur des TALE Base Editors lors du congrès annuel de l’ESGCT NEW YORK, 07 oct. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome pour développer des thérapies cellulaires et géniques innovantes pour le traitement de maladies graves, a annoncé aujourd’hui que des résultats mettant en évidence le fort potentiel de l’ADN circulaire simple brin (CssDNA) comme matrice non virale univers...

21h / 18m 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights PARIS, Sept. 03, 2025 (GLOBE NEWSWIRE) -- (Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of votingrights08/31/2025100,325,22989,428,230   For further information on Cellectis, please contact: Media contacts:Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations contact:Arthur Stril...

September 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch